FIBRONEER-IPF – A Phase 3 Clinical Trial
Boehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF, a Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF). Donald Zoz, clinical program leader at Boehringer Ingelheim, will tell us more about this clinical trial on July 12!